Intravenous Iron, Inflammation, and Oxidative Stress: Is Iron a Friend or an Enemy of Uremic Patients?

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 40-45

  Garneata, Liliana ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37049012436     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.009     Document Type: Article

References (32)

1. Locatelli F., Aljama P., Barany P., et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 Suppl 2 (2004) ii1-ii41
2. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease (2001), National Kidney Foundation, New York pp 35-49
3. Cavill I. Intravenous iron as an adjuvant therapy: a two-edged sword?. Nephrol Dial Transplant 18 Suppl 8 (2003) viii24-viii28
4. Schustack A., Meshiaj D., Waiss Z., and Gotloib L. Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow-up of up to 8 years on 16 patients. Clin Nephrol 23 (1985) 303-306
5. Silverberg D.S., Iaina A., Peer G., et al. Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27 (1996) 234-237
6. Silverberg D.S., Blum M., Agbaria Z., Schwartz D., Zubkov A., and Iaina A. Intravenous iron for the treatment of the predialysis patient. Kidney Int 55 Suppl 69 (1999) S79-S85
7. Silverberg D.S., Blum M., Agbaria Z., et al. The effect of iv iron alone or in combination with low-dose erythropoietin in the rapid correction of anaemia of chronic renal failure in the predialysis period. Clin Nephrol 55 (2001) 212-219
8. Deicher R., and Hörl W.H. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant 19 (2004) 521-523
9. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 18 (2007) 394-400
10. Valderrábano F., Hörl W.H., Macdougall I.C., et al. Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 18 (2003) 89-101
11. Gotloib L., Silverberg D., Fudin R., and Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19 (2006) 161-167
12. Hörl W.H. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18 (2007) 382-393
13. Mircescu G, Gherman-Cǎprioarǎ M, Covic A, et al: Best practice guidelines. Anemia secondary to chronic kidney disease [in Romanian]. Bucharest: Ed. Infomedica, 2005
14. Mircescu G., Garneata L., Cǎpuşǎ C., and Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 21 (2006) 120-124
15. Stoves J., Inglis H., and Newstead C.G. A randomized study of oral vs. intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16 (2001) 967-974
16. Glickman JD: Morbidity of anemia in patients with chronic kidney disease, ANNA CE Satellite Symposium, 2004, http://www.hdcn.com/symp/04nnai/gli/gli.htm (accessed April 7, 2007)
17. Van Wyck D.B., Roppolo M., Martinez C.O., Mazey R.M., McMurray S., and United States Iron Sucrose (Venofer®) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68 (2005) 2846-2856
18. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 69 (2006) 1259-1263
19. Feldman H.I., Santanna J., Guo W., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 (2002) 734-744
20. Hoen B., Paul-Dauphin A., and Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57 (2002) 457-461
21. Aronoff G.R., Bennett W.M., Blumenthal S., et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 66 (2004) 1193-1198
22. Esposito B.P., Breuer W., Slotki I., and Cabantchik Z.I. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32 Suppl 1 (2002) 42-49
23. Weiss G., Meusburger E., Radacher G., Garimorth K., Neyer U., and Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64 (2003) 572-578
24. Agarwal R., Vasavada N., Sachs N.G., and Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
25. Cǎpuşǎ C., Stoian I., Mircescu G., et al. Does intravenous iron administration acutely influence the erythrocyte antioxidant status in hemodialysis patients?. Nephrol Dial Transplant 21 Suppl 4 (2006) iv202
26. Maruyama Y., Nakayama M., Yoshimura K., Nakano H., et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-20-deoxyguanosine levels. Nephrol Dial Transplant 22 (2007) 1407-1412
27. Agarwal R. Overcoming barriers that inhibit proper treatment of anemia. Kidney Int 69 Suppl (2006) S9-S12
28. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Michael B., and Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
29. Mircescu G., Cǎpuşǎ C., Garneata L., et al. The relationship between long-term intravenous iron therapy and morbidity in hemodialysis patients: one center experience. Nephrol Dial Transplant 21 Suppl 4 (2006) iv161
30. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis 49 (2007) 736-743
31. Lahera V., Goicoechea M., Vinuesa S.G., Oubiña P., et al. Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol 17 Suppl (2006) S174-S177
32. Agarwal R: Maximizing patient outcomes through IV iron therapy and appropriate iron measures. Independent benefits of iron: beyond raising Hgb levels, in Agarwal R, Coyne D (eds): 7th International Conference on Dialysis: Advances in ESRD 2005, http://www.hdcn.com/symp/05rrisat/aga/aga.htm (accessed April 14, 2007)